Kristin Strumane

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.

Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed Hepatotoxicity.

Journal: Clinical and translational science

Published: November 24, 2025

Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects.

Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects.

Journal: Journal for immunotherapy of cancer

Published: March 24, 2025

Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.

Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism.

Journal: Molecular cancer therapeutics

Published: January 17, 2020

DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.

DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.

Journal: Blood cancer journal

Published: November 05, 2019

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Journal: Haematologica

Published: October 02, 2018

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.

Journal: PLoS biology

Published: August 20, 2015

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.

Journal: Molecular immunology

Published: December 16, 2014

Complement is activated by IgG hexamers assembled at the cell surface.

Complement is activated by IgG hexamers assembled at the cell surface.

Journal: Science (New York, N.Y.)

Published: March 15, 2014

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.

Journal: mAbs

Published: February 05, 2014

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 13, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026